Le Lézard
Classified in: Science and technology, Business
Subject: ACC

Number of shares and votes in EQT


STOCKHOLM, March 28, 2024 /PRNewswire/ -- The total number of votes in EQT AB (publ) ("EQT") changed during March 2024 as a result of a conversion of 348,106 class C shares to 348,106 ordinary shares. The conversion was made pursuant to EQT's previous Share Program. The total number of votes has increased by 313,295.4, while the total number of shares issued is unchanged.

The number of shares and votes in EQT as of 28 March 2024 is set out in the table below.


Ordinary shares

Class C shares1

Total

Number of issued shares2 

1,245,048,412 
                                   (1,245,048,412 votes)

881,555 
                                    (88,155.5 votes)

1,245,929,967 
                                   (1,245,136,567.5 votes) 

Number of shares owned by EQT AB3 

60,474,829

-

60,474,829

Number of outstanding shares

1,184,573,583 
                                   (1,184,573,583 votes)

881,555 
                                    (88,155.5 votes)

1,185,455,138 
                                    (1,184,661,738.5 votes)

1 Carry one tenth (1/10) of a vote.2 Total number of shares in EQT AB, i.e. including the number of shares owned by EQT AB and the number of shares outstanding.3 EQT AB shares owned by EQT AB are not entitled to dividends or carry votes at shareholders' meetings.

This press release is published for regulatory reasons.

Contact

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Press Office, [email protected], +46 8 506 55 334

This is information that EQT AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 28 March 2024.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/number-of-shares-and-votes-in-eqt,c3953936

The following files are available for download:

https://mb.cision.com/Main/87/3953936/2702176.pdf

EQT AB - Press release (28 March 2024) EN

https://news.cision.com/eqt/i/eqt-stockholm,c3284139

EQT Stockholm

 


These press releases may also interest you

at 00:45
At Last, a Worldwide Groundbreaking Solution to Address the Unhoused Crisis
Claudio Bono, Managing Director for two independent Hotels in Silicon Valley, is thrilled to unveil a groundbreaking platform and an idea that will transform the landscape of the urgent unhoused crisis and social issues. Leveraging his extensive...

26 avr 2024
Flash News: OKX Wallet Integrates with Side Protocol
OKX, a leading Web3 technology company, today announced the integration of Side Protocol with the OKX Wallet. Side Protocol is a cross-chain middleware protocol designed to enable seamless communication and asset transfer between heterogeneous...

26 avr 2024
Flash News: OKX Wallet Integrates with Bitrubo
OKX, a leading Web3 technology company, today announced the integration of Biturbo with the OKX Wallet. Bitrubo is an innovative layer 2 solution that brings the power of Ethereum's smart contracts to the Bitcoin network. Biturbo is designed as an...

26 avr 2024
Cognitive Security Market Projected to Reach $134.26 billion by 2030 - Exclusive Report by 360iResearch
The report titled "Cognitive Security Market by Component (Services, Solutions), Security Type (Application, Cloud, Cybersecurity), Application, Deployment Mode, Enterprise Type, Vertical - Global Forecast 2024-2030" is now available on...

26 avr 2024
Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

More news about Science and technology...


News published on and distributed by: